Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

US STOCKS-Futures dip as Chinese data disappoints, tariff deadline closes in

Published 12/09/2019, 08:23 PM
Updated 12/09/2019, 08:24 PM
US STOCKS-Futures dip as Chinese data disappoints, tariff deadline closes in
ARQL
-

(For a live blog on the U.S. stock market, click LIVE/ or
type LIVE/ in a news window.)
* Futures: Dow, S&P 500 and Nasdaq down 0.13%

By Shreyashi Sanyal
Dec 9 (Reuters) - U.S. stock index futures edged lower on
Monday as weak data from China brought back fears of a slowdown
in the world's second-biggest economy, while investors awaited
more news on trade ahead of a tariff deadline later in the week.

China's exports in November shrank for the fourth
consecutive month, underscoring persistent pressures on
manufacturers from the Sino-U.S. war but growth in imports may
be a sign that Beijing's stimulus steps are helping to stoke
demand. Wall Street gained ground on Friday, driven by a blowout
domestic jobs report and optimism around the U.S.-China trade
negotiations. All three major U.S. stock indexes are hovering
within 1% of record highs set two weeks ago.
In a quiet start to the week, market participants are
expected to keep a close watch on trade as planned U.S. tariffs
on Chinese imports kick in on Dec. 15 that will cover several
consumer products, including mobile phones and toys.
Also in focus is the Federal Open Market Committee's two-day
policy meeting, which starts on Tuesday.
At 7:00 a.m. ET, Dow e-minis 1YMcv1 were down 37 points,
or 0.13%. S&P 500 e-minis EScv1 were down 4 points, or 0.13%
and Nasdaq 100 e-minis NQcv1 were down 10.75 points, or 0.13%.
Among stocks, 3M Co MMM.N shares dropped 1% in premarket
trading after Citigroup cut its rating on the industrial
conglomerate's shares to "neutral".
Macy's Inc M.N fell 2% after Goldman Sachs reportedly
downgraded shares of the department store operator to "sell".

In deals, Merck & CO MRK.N said it would buy cancer drug
developer ArQule Inc ARQL.O for $2.7 billion in cash to beef
up its portfolio of blood cancer treatments. Shares of ArQule
doubled in value following the news.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.